Exinalda"TM" - new treatment for fat malabsorption in patients with cystic fibrosis

05-Jul-2005

Arexis AB has selected Exinalda"TM" as the product name for its treatment for fat malabsorption. Exinalda"TM" has been documented in two successful clinical phase II studies and has an Orphan Drug Designation in the EU for the treatment of fat malabsorption in patients with exocrine pancreatic insufficiency and cystic fibrosis.

Exinalda(TM) represents a completely new approach for improving the absorption of lipids and fat soluble vitamins from food. Approximately 90 per cent of the patients suffering from cystic fibrosis have problems digesting fat, caused by pancreatic insufficiency, which can lead to malnutrition, growth failure and increased mortality.

After completing two successful phase II studies and being granted orphan drug status in the EU, Arexis launched the product name Exinalda(TM) for its new treatment of fat malabsorption in patients with cystic fibrosis.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances